For pralsetinib, the most common any grade treatment-related AEs included elevated aspartate aminotransferase (AST) level (34%), anaemia (24%), elevated alanine aminotransferase (ALT) level (23%), and hypertension (22%); while for selpercatinib, the most observed the majority of treatment-related toxicities included diarrhoea (25%), increased AST (22%), increased ALT (20%), and hypertension (17%) (Drilon et al. This evidence concerns the gene GPT and anemia.